The sale is routine and part of a pre-arranged plan, not an isolated event. Traders should monitor for further sales under this plan, but the current filing alone does not signal material concern. However, the cumulative insider selling over $14.6M in one month may warrant attention if it continues.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 16 $86.14entry
- T+1 · 7mo ago +1.82%α +0.61% · $87.71
- T+5 · 7mo ago +1.20%α +0.21% · $87.17
- T+20 · 6mo ago −0.64%α −6.45% · $85.59
- T+60 · 4mo ago +28.16%α +21.12% · $110.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Jeremy Chadwick, an officer of Kymera Therapeutics, filed a Form 144 to notify the SEC of his intent to sell 1,300 shares of common stock, representing a small portion of his holdings. This is part of a broader 10b5-1 trading plan, following a series of prior sales totaling over $14.6M in the past month.
Key Facts
- Jeremy Chadwick, an officer of Kymera Therapeutics, filed Form 144 to propose selling 1,300 shares.
- The shares are common stock, to be sold on or after April 15, 2026, via Morgan Stanley Smith Barney LLC.
- This filing is part of an existing 10b5-1 plan, with recent sales by Chadwick totaling approximately $14.6 million over the past month.
- The proposed sale is relatively small compared to prior transactions and the company's $7.3B market cap.
Financial Impact
Approximately $116,824.50 (based on $89.86/share), representing a minimal portion of recent insider selling activity
Risk Factors
- Perception of insider confidence if selling persists under 10b5-1 plan amid no fundamental updates
- Potential for increased share supply if larger blocks are sold in coming periods
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-003490 |
| Document: 0001950047-26-003490-index.html | 0001950047-26-003490 |
| Document: 0001950047-26-003490.txt | 0001950047-26-003490 |
Track record
37 reports on KYMR
7 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers